试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-28
Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
编号:NCT03400254登记状态:入组前撤回企业 / 申办者:Abramson Cancer Center at Penn Medicine
药物 / 成分:Hydroxychloroquine (HCQ)、Gedatolisib
登记的停止原因(原文):due to business decision regarding the study drug.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-27
Rejuvenated, Washed Packed Red Blood Cells in Pediatric Cardiac Surgery
编号:NCT02485366登记状态:入组前撤回企业 / 申办者:Duke University
药物 / 成分:Rejuvesol、Cardiac surgery
登记的停止原因(原文):Product unavailability
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-27
Hyperbaric Oxygen Therapy After Stroke - PILOT
编号:NCT04149379登记状态:入组前撤回企业 / 申办者:Norwegian Underwater Intervention (NUI)
药物 / 成分:Hyperbaric oxygen
登记的停止原因(原文):Because of the economic consequences of the COVID-19 pandemic 2020
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-27
Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124
编号:NCT04176653登记状态:入组前撤回企业 / 申办者:Silence Therapeutics plc
药物 / 成分:SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo
登记的停止原因(原文):Study stopped prior to subject administered first dose, due to COVID-19
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-24
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
编号:NCT03920839登记状态:入组前撤回企业 / 申办者:Incyte Corporation
药物 / 成分:Retifanlimab、Gemcitabine、Cisplatin、Pemetrexed
登记的停止原因(原文):As of November 4, 2019 the study was halted prematurely and will not resume.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-22
Randomized, Double-blind, Placebo, Controlled Cross Over Design Topical Morphine for Analgesia in Pediatric Procedures
编号:NCT02300194登记状态:入组前撤回企业 / 申办者:Hospital General de Niños Pedro de Elizalde
药物 / 成分:Topic Morphine、Placebo
登记的停止原因(原文):Withdrawn by investigators
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-22
Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome
编号:NCT03617224登记状态:入组前撤回企业 / 申办者:University of Texas Southwestern Medical Center
药物 / 成分:TSEBT、TSEBT and pembrolizumab
登记的停止原因(原文):Unable to enroll patients that met enrollment criteria.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-22
Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients
编号:NCT03809455登记状态:入组前撤回企业 / 申办者:UNICANCER
药物 / 成分:Fentanyl citrate、Placebo
登记的停止原因(原文):Study was cancelled by Sponsor.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-22
Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study
编号:NCT03949842登记状态:入组前撤回企业 / 申办者:GlaxoSmithKline
药物 / 成分:Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists、Fluticasone furoate/umeclidinium/vilanterol
登记的停止原因(原文):The decision to end the study was based on a change in GSK strategy. No subjects were enrolled into the study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-04-21
Acetazolamide to Prevent Post Operative CSF Leak
编号:NCT02902133登记状态:入组前撤回企业 / 申办者:University of Miami
药物 / 成分:Acetazolamide
登记的停止原因(原文):No participants were identified per inclusion/exclusion criteria
查看官方原始记录 ↗